Estados de hipercoagulabilidad
Downloads
Fueron estudiados 20 individuos normales tomados como controles y 122 pacientes adultos de ambos sexos, distribuidos equitativamente en las siguientes entidades clínicas: Sepsis, Toxemia, Cáncer, Estados post-operatorios, Tromboflebitis, EPOC, Uremia, Hiperlipidemia, bajo el efecto de Anticonceptivas, Trombosis Arterial e Infarto del Miocardio. Para tratar de detectar probables estados de hipercoagulabilidad, se les practicaron los siguientes exámenes de laboratorio: T. de Trombina. Fibrinógeno cuantitativo. Productos de degradación del Fibrinógeno. Fracciones D y E de los productos de degradación del Fibrinógeno. Dosificación de la fracción coagulante del Factor VIII. Antígeno del Factor VIII. Relación entre el Antígeno y la fracción coagulante del Factor VIII. Dosificación de Antitrombina III. En promedio, encontramos anormalidad en los siguientes resultados: Fibrinógeno aumentado en el 66%. Productos de degradación del Fibrinógeno elevado en el 55% por la prueba de Merskey y en el 46% por la prueba del sulfato de Protamina. Disminución en la concentración de la Antitrombina III en el 34%. Aumento en las fracciones D y E de los productos de degradación del Fibrinógeno, en un promedio del 33%. Aumento en la fracción coagulante del Factor VIII en el 28% y en el Antígeno del Factor VIII y en la relación Antígeno, fracción coagulante del Factor VIII en el 23%, El tiempo de Trombina se demostró acortado sólo en el 17%. En esta primera etapa del estudio de probables Estados de Hipercoagulabilidad, encontramos como pruebas indicativas y accesibles dentro de un panorama práctico: El Fibrinógeno cuantitativo, los productos de degradación del Fibrinógeno por las pruebas del Merskey y del Sulfato de Protamina respectivamente, los niveles de Antitrombina III, las fracciones D y E de los productos de degradación del Fibrinógeno y la dosificación de la fracción coagulante del Factor VIII.
Twenty healthy individuals as normal controls and 120 adults patients of both sexes were studied, distributed equally in the following clinical entities: Sepsis, Toxemia, Cancer, Post operative states, Thrombophebitis, POCD, Uraemia, Hyperlipidemia, under the effect of anticonceptive drugs, Arterial Thrombosis and Myocardial Infarction. In order to detect probable Hypercoagulability states, the following laboratory tests were performed: Thrombin time, Dosification of Fibrinogen, Fibrinogen Degradation Products (FDP), Fractions D and E of the Fibrinogen Degradations Products, Dosification of Coagulation Fraction of Factor VIII, Factor VIII Antigen, Ratio Factor VIII Antigen/Coagulation Fraction of Factor VIII and levels of Antithrombin III. In average, we found abnormalities in the following results: High levels of Fibrinogen in 66%. Fibrinogen Degradation Products abnormals in 55% for the Merskey method and 46% in the Protamine Sulfate test. Low concentration of Antithrombin III in 34%. High levels in fractions D and E of Fibrinogen Degradation Products in 33%. Increase in the Coagulation Fraction of Factor VIII in 28% and high ratio Factor VIII Antigen/Coagulation Fraction of Factor VIII in 23%. The abnormal Thrombin time only in the 17% of our patients. In the first step of the study of probable Hypercoagulability states, we found as indicatives and fesible tests from a practical point of view: The levels of Fibrinogen, the Fibrinogen Degradation Products for the Merskey method and the Protamine Sulfate test respectively, the levels of Antithrombin III, the fractions D and E of the Fibrinogen Degradation Products and the dosification of Coagulations Fraction of Factor VIII.
How to Cite
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Download Citation
Article abstract page views
Downloads
License
Copyright
Authors must agree to transfer to the Revista de la Facultad de Medicina the copyright of the articles published in the Journal. The publisher has the right to use, reproduce, transmit, distribute and publish the articles in any form. Authors will not be able to permit or authorize the use of their published paper without the written consent of the Journal.
The letter of copyright transfer and the letter of authorship responsibility must be submitted along with the original paper through the Journal OJS platform. These files are available in https://goo.gl/EfWPdX y https://goo.gl/6zztk4 and must be uploaded in step 4 (supplementary files).
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).